Works matching DE "ANDROGEN deprivation therapy"
Results: 873
Osteonecrosis of Jaws in Prostate Cancer Patients Treated With Antiresorptive Drugs: A Review.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Primary management of prostate cancer by universal health coverage effective coverage index.
- Published in:
- World Journal of Urology, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s00345-025-05530-7
- By:
- Publication type:
- Article
Primary management of prostate cancer by universal health coverage effective coverage index.
- Published in:
- World Journal of Urology, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s00345-025-05530-7
- By:
- Publication type:
- Article
From testosterone to mitochondria: unveiling the metabolic consequences of abiraterone therapy.
- Published in:
- World Journal of Urology, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s00345-025-05457-z
- By:
- Publication type:
- Article
Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer.
- Published in:
- World Journal of Urology, 2024, v. 42, n. 1, p. 1, doi. 10.1007/s00345-024-05316-3
- By:
- Publication type:
- Article
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.
- Published in:
- World Journal of Urology, 2024, v. 42, n. 1, p. 1, doi. 10.1007/s00345-024-05323-4
- By:
- Publication type:
- Article
Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study.
- Published in:
- World Journal of Urology, 2024, v. 42, n. 1, p. 1, doi. 10.1007/s00345-024-05286-6
- By:
- Publication type:
- Article
Re: letter to the editor for the article "Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy".
- Published in:
- World Journal of Urology, 2024, v. 42, n. 1, p. 1, doi. 10.1007/s00345-024-05255-z
- By:
- Publication type:
- Article
Olaparib bei biochemischem Rezidiv des High-risk-Prostatakarzinoms nach Prostatektomie.
- Published in:
- 2025
- By:
- Publication type:
- Book Review
Early and repetitive novel-tracer PET-guided stereotactic body radiotherapy for nodal oligorecurrent prostate cancer after definitive first-line therapy.
- Published in:
- Strahlentherapie und Onkologie, 2025, v. 201, n. 1, p. 36, doi. 10.1007/s00066-024-02304-9
- By:
- Publication type:
- Article
The Effect of Androgen Deprivation on the Expression of Connexin-43 mRNA in the Heart.
- Published in:
- Journal of Cell & Molecular Research, 2021, v. 13, n. 1, p. 65, doi. 10.22067/jcmr.2021.71395.1010
- By:
- Publication type:
- Article
Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study.
- Published in:
- European Journal of Hybrid Imaging, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41824-023-00178-1
- By:
- Publication type:
- Article
Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy.
- Published in:
- Current Developments in Nutrition, 2021, v. 5, n. 11, p. 1, doi. 10.1093/cdn/nzab106
- By:
- Publication type:
- Article
Intermittent androgen suppression in the management of prostate cancer: a phase II comparative study.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2000, v. 3, n. 1, p. S20, doi. 10.1038/sj.pcan.4500444
- By:
- Publication type:
- Article
Can PD-1 expression in prostate cancer help to predict response to single ADT in an Indonesian population?
- Published in:
- Journal of Experimental & Clinical Medicine / Deneysel ve Klinik Tip Dergisi, 2024, v. 41, n. 3, p. 474, doi. 10.52142/omujecm.41.3.4
- By:
- Publication type:
- Article
Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 11, p. 1642, doi. 10.3390/biom13111642
- By:
- Publication type:
- Article
Yin Yang 1 promotes the neuroendocrine differentiation of prostate cancer cells via the non‐canonical WNT pathway (FYN/STAT3).
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 10, p. 1, doi. 10.1002/ctm2.1422
- By:
- Publication type:
- Article
Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
- Published in:
- Clinical & Translational Medicine, 2022, v. 12, n. 9, p. 1, doi. 10.1002/ctm2.1028
- By:
- Publication type:
- Article
Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 7, p. 1, doi. 10.1002/ctm2.495
- By:
- Publication type:
- Article
Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 6, p. 1, doi. 10.1002/ctm2.449
- By:
- Publication type:
- Article
Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1345322
- By:
- Publication type:
- Article
Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1240939
- By:
- Publication type:
- Article
Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1110807
- By:
- Publication type:
- Article
The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1185530
- By:
- Publication type:
- Article
Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1265812
- By:
- Publication type:
- Article
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1210487
- By:
- Publication type:
- Article
Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1107134
- By:
- Publication type:
- Article
Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER database (2004 -2018).
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1165188
- By:
- Publication type:
- Article
Cardiovascular outcomes after curative prostate cancer treatment: A population-based cohort study.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1121872
- By:
- Publication type:
- Article
Choline PET/CT in recurrent prostate cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1079808
- By:
- Publication type:
- Article
First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1126476
- By:
- Publication type:
- Article
High infiltration of CD209<sup>+</sup> dendritic cells and CD163<sup>+</sup> macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1205266
- By:
- Publication type:
- Article
The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1009634
- By:
- Publication type:
- Article
Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
- Published in:
- International Journal of Cancer, 2024, v. 155, n. 7, p. 1248, doi. 10.1002/ijc.35052
- By:
- Publication type:
- Article
Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 6, p. 1082, doi. 10.1002/ijc.34778
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2023
- Publication type:
- Correction Notice
Long‐term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population‐based competing risk analysis.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 4, p. 756, doi. 10.1002/ijc.34557
- By:
- Publication type:
- Article
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long‐term clinical monitoring.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 10, p. 2166, doi. 10.1002/ijc.34448
- By:
- Publication type:
- Article
Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 11, p. 1925, doi. 10.1002/ijc.34204
- By:
- Publication type:
- Article
Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 7, p. 1109, doi. 10.1002/ijc.34058
- By:
- Publication type:
- Article
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration‐resistant cancer patients.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 7, p. 1166, doi. 10.1002/ijc.33834
- By:
- Publication type:
- Article
Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36253-1
- By:
- Publication type:
- Article
Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-33069-3
- By:
- Publication type:
- Article
miRNA Signatures as Predictors of Therapy Response in Castration-Resistant Prostate Cancer: Insights from Clinical Liquid Biopsies and 3D Culture Models.
- Published in:
- Genes, 2025, v. 16, n. 2, p. 180, doi. 10.3390/genes16020180
- By:
- Publication type:
- Article
Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation.
- Published in:
- Prostate Cancer (20903111), 2023, p. 1, doi. 10.1155/2023/6641707
- By:
- Publication type:
- Article
The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review.
- Published in:
- Prostate Cancer (20903111), 2022, v. 2022, p. 1, doi. 10.1155/2022/5324600
- By:
- Publication type:
- Article
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Prostate Cancer (20903111), 2022, p. 1, doi. 10.1155/2022/5454727
- By:
- Publication type:
- Article
High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy.
- Published in:
- Prostate Cancer (20903111), 2021, p. 1, doi. 10.1155/2021/5574067
- By:
- Publication type:
- Article
A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
- Published in:
- Clinical Epigenetics, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13148-021-01119-0
- By:
- Publication type:
- Article
Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature.
- Published in:
- 2021
- By:
- Publication type:
- journal article